Data as of Oct 28, 2026.

vsCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Across categories

IGIB vs XBI: Differences, Returns & Fees

Share
Share on XDownload as PDF

Over the year to Oct 28, 2026, IGIB returned −1.8% to XBI's +41.2%, and IGIB charges 0.04% to XBI's 0.35%.

askIQ about this page

askIQ about IGIB and XBI

Net assets: $19.5bn on Oct 28, 2026 for iShares 5-10 Year Investment Grade Corporate Bond ETF, and $10.3bn on Oct 27, 2026 for State Street SPDR S&P Biotech ETF.

At a glance
−1.8%
IGIB total return, 1 year
+41.2%
XBI total return, 1 year
0.04%
IGIB expense ratio
0.35%
XBI expense ratio

Pair scorecard

IGIB costs 0.31 points a year less; their one-year returns differ by 43.0 points; IGIB is 1.9 times larger.

IGIB vs XBI: Differences, Returns & Fees
MeasureIGIBXBI
Return
Total return, 1 year−1.8%+41.2%
Drawdown
Below its high3.2%, high on Feb 27, 2026
Below its all-time high8.9%, high on Feb 8, 2021
Benchmark
What it tracksICE BofA 5-10 Year US Corporate IndexBiotech
Cost and size
Expense ratio0.04%0.35%
Net assets, as of Oct 26, 2026$19.5bn$10.2bn
Active share vs the S&P 50098%
Holdings
Holdings in common0%
In the S&P 500, by weight13%
Top ten holdings, share of the fund18%

Holdings in common uses holdings dated Oct 27, 2026. Method

Risk and return

Jan 19, 2007 to Oct 23, 2026 · 1,031 weekly returns
IGIB XBI
Return
Total return edge XBI +104.0% +878.3%
Annualized edge XBI +3.7% +12.2%
Price return edge XBI +1.8% +825.0%
Risk
Volatility edge IGIB 6.0% 29.6%
Max drawdown edge IGIB −20.0% −61.5%
Risk-adjusted
Sharpe edge XBI 0.37 0.48
Sortino edge XBI 0.49 0.71
Calmar edge XBI (slight) 0.18 0.20
Reading

XBI returned more: +878.3% to +104.0%. IGIB swung less: 6.0% to 29.6%. IGIB fell less at its worst: −20.0% to −61.5%.

Full scorecard

9 measures, with how each is measured
Open ↓
Risk and return: IGIB vs XBI: Differences, Returns & Fees
MeasureIGIBXBIEdgeHow it is measured
Return
Total return+104.0%+878.3%XBIPrice change plus distributions, reinvested.
Annualized+3.7%+12.2%XBITotal return as a yearly rate.
Price return+1.8%+825.0%XBIPrice change alone, distributions left out.
Risk
Volatility6.0%29.6%IGIBSpread of weekly returns, annualized. Lower is steadier.
Downside deviation4.4%20.2%IGIBLike volatility, counting only weeks below the Treasury bill rate.
Max drawdown−20.0%−61.5%IGIBDeepest fall from a high to the low after it.
Risk-adjusted
Sharpe0.370.48XBIReturn above Treasury bills per unit of volatility.
Sortino0.490.71XBIReturn above Treasury bills per unit of downside deviation.
Calmar0.180.20XBI (slight)Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 1,031 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

0%

By the books each fund has filed, IGIB and XBI hold 0% of their money in the same securities at the same weight. Holdings dated Oct 27, 2026.

0 half 100%

half

0% in common

Positions both hold · largest shared weight first IGIB XBI
Only in one fund ↓
Only in IGIB
AMAZON.COM INC 0.22%
META PLATFORMS INC 0.22%
META PLATFORMS INC 0.20%
ANHEUSER-BUSCH COMPANIES LLC 0.19%
BANK OF AMERICA CORP MTN 0.19%
SPACE EXPLORATION TECHNOLOGIES COR 144A 0.19%
BANK OF AMERICA CORP MTN 0.18%
BANK OF AMERICA CORP MTN 0.18%
Only in XBI
MODERNA INC 2.24%
TWIST BIOSCIENCE CORP 1.86%
NATERA INC 1.82%
BIOGEN INC 1.75%
HALOZYME THERAPEUTICS INC 1.75%
UNITED THERAPEUTICS CORP 1.71%
AMGEN INC 1.68%
ABBVIE INC 1.67%
Check overlap with more funds →

Side by side

IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF XBI State Street SPDR S&P Biotech ETF
Where it sits Bond ETF Thematic ETF
What it is Tracks an index of 5-10 Year Investment Grade Corporate Bond Biotech
Total return, 1 year −1.8% +41.2%
Expense ratio 0.04% 0.35%
Holdings 3064 165
Net assets, IGIB as of Oct 28, 2026 and XBI as of Oct 27, 2026 $19.5bn $10.3bn

IGIB and XBI on the fields both publish, as of Oct 28, 2026. Source: ETFIQ.

Client brief · page 1 of 2 Report BR-0BB6CCD814

IGIB and XBI do different jobs. What does each one do in a portfolio?

  1. What each follows. IGIB follows ICE BofA 5-10 Year US Corporate Index and XBI follows Biotech.
  2. Holdings in common. 0% of the weight is in the same securities (holdings dated Oct 27, 2026).
  3. One-year total return. Over 1 year to Oct 28, 2026 IGIB returned −1.8% and XBI +41.2% with distributions reinvested, a gap of 43.0 points.

Data as of Oct 28, 2026.

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

IGIB and XBI flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
IGIB

IGIB tracks an index of 5-10 Year Investment Grade Corporate Bond. Over the year to Oct 28, 2026 it returned −1.8% with distributions reinvested. The prospectus expense ratio is 0.04% a year. It sat 3.2% below its high of Feb 27, 2026 on Oct 28, 2026.

XBI

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 18% of the fund across 165 positions, as published by its issuer for Oct 27, 2026. Over the year to Oct 28, 2026 the fund returned +41.2% with distributions reinvested. It sits 8.9% below its all-time high of Feb 8, 2021.

Questions people ask

Are IGIB and XBI in the same category?
IGIB is a bond ETF and XBI is a thematic ETF, so they do different jobs. The table compares what both publish: return, cost and holdings.
Which returned more over the last year, IGIB or XBI?
In the year to Oct 28, 2026, with distributions reinvested, IGIB returned −1.8% and XBI +41.2%.
Which is cheaper, IGIB or XBI?
IGIB is cheaper, by 0.31 percentage points a year. That is about $31 on $10,000 held for a year. Fees come from each fund's prospectus.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, IGIB against XBI, data as of Oct 28, 2026. https://etfiq.com/compare/any/igib-vs-xbi

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.